Skip to main content

Table 2 Radiogenomic features of glioma biomarkers

From: Clinical applications of artificial intelligence and radiomics in neuro-oncology imaging

 

Glioma biomarker

Features

1

IDH

IDH mutant

 Predominantly hypoenhancing diffuse gliomas

 80% LGG and 10% GBM

 Better survival

IDH wild type

 Predominantly enhancing gliomas

 90% of GBM

 Worse survival

2

1P/19q codeletion

30% of LGG

1P/19q codeletion + IDH mutant glioma

 Defines oligodendroglioma

 “poorly circumscribed” margins

1P/19q non codeletion + / − IDH mutant glioma

 Defines astrocytoma

 “circumscribed” margins

 (T2-FLAIR mismatch) pattern

3

MGMT mutation

33–57% of diffuse glioma patients

Better prognosis

4

EGFR mutation

40% of glioblastoma patients

Splice variant (EGFRvIII)

31% of glioblastoma

  1. IDH isocitrate dehydrogenase, MGMT methylation of O-6-methylguanine-DNA-methyltransferase, EGFR epidermal growth factor receptor